10-day extension moves Latrobe Magnesium offer deadline to 26 October

Entitlement Offer Deadline Moves To 26 October

Latrobe Magnesium Limited (ASX:LMG) has extended the closing date of its fully underwritten non-renounceable entitlement offer by 10 days, giving eligible Australian and New Zealand shareholders until 5.00pm AEDT on Monday, 26 October to participate.

The company said the decision reflected recent market volatility and delays in shareholders receiving the prospectus and entitlement forms by mail. The extension does not change the offer terms, according to the announcement.

Capital Raising Follows A$8.5 Million Equity Package

The offer is the entitlement component of Latrobe Magnesium's broader A$8.5 million equity raising, which included a A$5.1 million institutional placement and a fully underwritten A$3.4 million entitlement offer. The earlier raising was intended to fund completion of the company's Latrobe Valley demonstration plant and advance initial work on its proposed South Carolina magnesium project. Existing shareholders who do not participate face dilution under the structure described in the earlier announcement.

The extension gives shareholders more time to assess that funding proposal, which was announced alongside the company's push towards first magnesium metal production. Latrobe had previously reported that the demonstration plant's magnesium metal circuit was moving through final installation, while its annual report disclosed a material uncertainty around the group's ability to continue as a going concern. Those issues were examined in the A$8.5 million equity raising, which included the entitlement offer now being extended.

Issue And Trading Dates Shift Into November

Latrobe expects to issue the new shares on 2 November, with trading on the ASX scheduled to start on 3 November. The timetable remains indicative and may change in accordance with the Corporations Act and ASX Listing Rules.

Shareholders can take up all or part of their entitlement, apply for additional shares up to 100% of their entitlement, or allow the entitlement to lapse. Because the offer is non-renounceable, an entitlement that is not exercised will not be sold or otherwise deliver value to its holder.

Participation And Funding Remain The Next Tests

The announcement does not disclose participation levels or alter the expected proceeds, and it leaves the company's wider development plans exposed to the risks outlined in its prospectus. The next useful signals will be how much of the offer is taken up, whether the revised timetable changes again, and whether the new shares are issued and admitted to trading as planned.